Wall Street brokerages expect Kalvista Pharmaceuticals Inc (NASDAQ:KALV) to announce $9.98 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Kalvista Pharmaceuticals’ earnings, with the highest sales estimate coming in at $30.00 million and the lowest estimate coming in at $3.00 million. Kalvista Pharmaceuticals posted sales of $3.89 million in the same quarter last year, which suggests a positive year over year growth rate of 156.6%. The firm is scheduled to report its next earnings report on Thursday, March 12th.
According to Zacks, analysts expect that Kalvista Pharmaceuticals will report full-year sales of $19.62 million for the current fiscal year, with estimates ranging from $13.30 million to $36.58 million. For the next financial year, analysts forecast that the firm will report sales of $9.57 million, with estimates ranging from $2.13 million to $16.57 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Kalvista Pharmaceuticals.
Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Tuesday, December 3rd. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.22. The firm had revenue of $3.92 million for the quarter, compared to analysts’ expectations of $3.23 million. Kalvista Pharmaceuticals had a negative net margin of 182.37% and a negative return on equity of 25.70%.
Shares of NASDAQ KALV traded down $0.19 during midday trading on Friday, reaching $13.96. 43,197 shares of the company were exchanged, compared to its average volume of 101,478. The stock’s 50-day moving average price is $16.21 and its 200-day moving average price is $14.52. The stock has a market cap of $259.31 million, a P/E ratio of -9.50 and a beta of 2.24. Kalvista Pharmaceuticals has a one year low of $9.86 and a one year high of $34.92. The company has a quick ratio of 10.30, a current ratio of 10.31 and a debt-to-equity ratio of 0.01.
In other news, insider Christopher Yea sold 1,500 shares of Kalvista Pharmaceuticals stock in a transaction on Friday, December 13th. The shares were sold at an average price of $17.05, for a total transaction of $25,575.00. Following the transaction, the insider now owns 83,168 shares in the company, valued at $1,418,014.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Thomas Andrew Crockett sold 5,400 shares of Kalvista Pharmaceuticals stock in a transaction on Monday, December 16th. The stock was sold at an average price of $17.06, for a total transaction of $92,124.00. Following the transaction, the chief executive officer now owns 248,320 shares in the company, valued at approximately $4,236,339.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,010 shares of company stock worth $170,720. 21.60% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the company. Rockefeller Capital Management L.P. acquired a new position in shares of Kalvista Pharmaceuticals during the fourth quarter worth $27,000. Cubist Systematic Strategies LLC acquired a new position in shares of Kalvista Pharmaceuticals during the second quarter worth $42,000. Tower Research Capital LLC TRC lifted its holdings in Kalvista Pharmaceuticals by 1,919.3% in the third quarter. Tower Research Capital LLC TRC now owns 3,877 shares of the specialty pharmaceutical company’s stock valued at $45,000 after buying an additional 3,685 shares during the period. Citigroup Inc. lifted its holdings in Kalvista Pharmaceuticals by 337.0% in the fourth quarter. Citigroup Inc. now owns 2,530 shares of the specialty pharmaceutical company’s stock valued at $45,000 after buying an additional 1,951 shares during the period. Finally, NEXT Financial Group Inc acquired a new position in Kalvista Pharmaceuticals in the fourth quarter valued at $83,000. Institutional investors own 90.59% of the company’s stock.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.